JPRN-UMIN000018431已完成未知
Retrospective study of Erythropoiesis STimulating Agent dose ReducTion on hemodialysis patients by using anti-thrombogenic membrane - RESTART Study
RESTART Study group0 个研究点目标入组 400 人开始时间: 2015年8月31日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •For 3 months before the beginning of observation and during observation period, patients who had fulfilled conditions below were excluded. 1) Patients who had been treated with other renal insufficiency therapies, continuous ambulatory peritoneal dialysis and hemodiafiltration, excluding hemodialysis. 2) Patients to whom Epoetin Beta Pegol (CERA) had been prescribed. 3) Patients to whom blood transfusion had been conducted. 4) Patients who had been hospitalized for more than 2 weeks. 5) Patients who had become pregnant or given birth. 6) Patients who had hematologic diseases excluding renal anemia. 7) Patients who had been treated for a malignant tumor. 8) Patients who is judged as the inadequate subject of this study by the doctor.
研究者
相似试验
进行中（未招募）
不适用
Effects of the dose of erythropoiesis stimulating agents on cardiac-cerebrovascular outcomes and quality of life in hemodialysis patients. The DOSe of Erythropoietins (DOSE) trial. - C.E. DOSEEUCTR2008-006014-20-ITCONSORZIO MARIO NEGRI SUD
招募中
不适用
Investigation of responses to erythropoiesis stimulating agents (ESA) for the initial treatment of renal anemia in patients with chronic kidney diseaseRenal anemia in chronic kidney diseaseJPRN-UMIN000009472Fukuoka Red Cross Hospital40
已完成
不适用
Effect of erythropoiesis-stimulating agents on the progression of chronic kidney disease: a retrospective studyChronic kidney disease patients with renal anemiaJPRN-UMIN000013311Department of Integrated Therapy for Chronic Kidney Disease, Graduate School of Medical Sciences, Kyushu University60
招募中
不适用
Prediction of response to Erythropoiesis stimulating agents by erythropoietin level and gene mutations in Low-risk Myelodysplastic syndromes1. Myelodysplastic syndrome2. Erythropoietin level3. Erythropoietin stimulating agentMyelodysplastic syndromeTCTR20200909001Ratchadaphiseksomphot Endowment Fund42
已完成
不适用
Comparative study of the sustained erythropoiesis-stimulating agents in patients with chronic kidney disease at predialysis stagechronic kidney diseaseJPRN-UMIN000008531Division of Nephrology, Hypertension and Endocrinology, Itabashi Hospital, Nihon University School of Medicn60